New research suggests that the lessening of amyloid-beta in the brain is behind cognitive decline in Alzheimer's and boosting ...

Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

A study shows that rising levels of brain protein Aβ42, not the reduction of amyloid plaques, better explains the cognitive ...

A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...

"Aβ42 is a protein that defends our brain from a variety of toxic and infectious exposures," Espay said. "In the process of reacting, it transforms into amyloid plaques. Amyloid plaques is made of ...

Researchers at the University of Cincinnati have discovered that Leqembi and Kisunla boost levels of a healthy form of amyloid beta (Aβ42) protein in the brain, even as they reduce its more toxic ...

For decades, the prevailing theory in the field has stated that a protein made up of 42 amino acids called amyloid-beta 42 (Aβ42) hardens into clumps called amyloid plaques, and those plaques ...